News blog
FDA approves antisense cholesterol drug
The US Food and Drug Administration announced yesterday that it has approved Kynamro (mipomersen), an “antisense” drug designed to treat a rare condition that causes the accumulation of extremely high levels of “bad” LDL cholesterol. Antisense drugs are strands of nucleic acid, such as DNA, designed to bind to and inactivate the RNA produced by a given gene.
Recent comments on this blog
Experiments reveal that crabs and lobsters feel pain
US research ethics agency upholds decision on informed consent
Chemistry credit disputes under the spotlight
Chemistry credit disputes under the spotlight
Contamination created controversial ‘acid-induced’ stem cells